New hope for hard-to-treat pancreatic cancer: drug combo aims to make tumors removable

This study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will have regular scans and blood tests to track response, and will be followed for survival after treatment ends.